Information Provided By: 
Fly News Breaks for April 8, 2019
CARA
Apr 8, 2019 | 09:22 EDT
Stifel analyst Annabel Samimy noted that Cara Therapeutics should be reporting its first pivotal readout of Phase 3 KALM-1 data for CKD-associated pruritus in the hemodialysis population within weeks and she believes the share "could move well past the mid-$20s" on a positive outcome. The analyst, who applies a 75% probability of success to Korsuva in CKD-associated pruritus, keeps a Buy rating and $26 price target on Cara shares and would be a buyer ahead of the data.
News For CARA From the Last 2 Days
There are no results for your query CARA
